Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.54 |
| ▸ | CDK2 | P24941 | 17/20 | 0.51 |
| ▸ | CDK1 | P06493 | 7/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2925237 | 0.82 | KCNH2 (0.38) | KCNH2CDK2CDK1 | |
| SCHEMBL2921456 | 0.82 | CDK5 (0.39) | KCNH2CDK2CDK1 | |
| SCHEMBL3226966 | 0.82 | CDK2 (0.51) | KCNH2CDK2CDK1 | |
| SCHEMBL1155944 | 0.82 | KCNH2 (0.39) | KCNH2CDK2CDK1 | |
| SCHEMBL4248122 | 0.80 | RPS6KA3 (0.36) | KCNH2CDK2CDK1 | |
| SCHEMBL27369648 | 0.78 | KCNH2 (0.76) | KCNH2CDK2CDK1 | |
| SCHEMBL4506293 | 0.77 | RPS6KA3 (0.34) | KCNH2CDK2 | |
| SCHEMBL3206999 | 0.75 | CDK2 (0.53) | KCNH2CDK2CDK1 | |
| SCHEMBL27369663 | 0.74 | CDK2 (0.75) | KCNH2CDK2CDK1 | |
| SCHEMBL3225072 | 0.73 | KCNH2 (0.53) | KCNH2CDK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034799-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | CEDARS SINAI MEDICAL CENTER (US) | 2024-02-01 | — | — | US | disclosed |
| US-20230279491-A1 | TREATMENTS FOR A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | CEDARS-SINAI MEDICAL CENTER | 2023-09-07 | — | — | US | disclosed |
| US-8134000-B2 | Imidazolyl pyrimidine inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8134000-B2 | Imidazolyl pyrimidine inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8134000-B2 | Imidazolyl pyrimidine inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2301928-A1 | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | disclosed |
| US-20110028489-A1 | Pyrimidine Derivatives and Their Use for Treating Bone-Related Disorders | ANDERSSON LARS | 2011-02-03 | — | — | US | disclosed |
| US-20110028489-A1 | Pyrimidine Derivatives and Their Use for Treating Bone-Related Disorders | ANDERSSON LARS | 2011-02-03 | — | — | US | disclosed |
| US-20110028489-A1 | Pyrimidine Derivatives and Their Use for Treating Bone-Related Disorders | ANDERSSON LARS | 2011-02-03 | — | — | US | disclosed |
| EP-2044058-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| EP-1869016-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007138268-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | disclosed |
| EP-1828183-A1 | 4- (4- (IMIDAZOL-4-YL) PYRIMIDIN-2-YLAMINO) BENZAMIDES AS CDK INHIBITORS | AstraZeneca AB (SE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007040436-A1 | USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER’S DISEASE | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007040436-A1 | USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER’S DISEASE | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007015064-A1 | IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | WO | disclosed |
| EP-1747187-A1 | METHOD FOR THE CONTINUOUS PRODUCTION OF AN AMINE | BASF AKTIENGESELLSCHAFT (DE) | 2007-01-31 | — | — | EP | disclosed |
| WO-2006095159-A1 | (IMIDAZOLO-5-YL)-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006064251-A1 | 4- (4- (IMIDAZOL-4-YL) PYRIMIDIN-2-YLAMINO) BENZAMIDES AS CDK INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| WO-2005110969-A1 | METHOD FOR THE CONTINUOUS PRODUCTION OF AN AMINE | BASF AKTIENGESELLSCHAFT (DE) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028489-A1 | Pyrimidine Derivatives and Their Use for Treating Bone-Related Disorders | TYMP, DPYD, HPRT1 | KCNH2 4545/4885CDK2 339/4885CDK1 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.